Previous 10 | Next 10 |
2023-12-03 06:54:00 ET Nike 's "Just Do It" tagline usually isn't great advice for investors. It's smart to conduct solid research on a stock before buying. That said, some outliers are so promising that spending a lot of time in analysis isn't so necessary. Three Motley Fool contri...
2023-12-03 04:00:32 ET Summary In 2023, AI and the Magnificent 7 took the lead, leaving non-tech blue chip companies trailing behind in the rearview mirror. Abbott Laboratories had a difficult last three years, with its stock price trading sideways as sales driven by COVID-19 plum...
2023-12-02 14:15:00 ET Increasingly popular weight loss drugs are not only benefitting individuals by reducing their waist lines. They could be a boon to apparel names. Based on a recent proprietary survey, Stifel believes that shedding pounds could impact spending trends, and in partic...
2023-12-02 05:53:00 ET It's rare for a prescription drug to become part of the cultural landscape. However, that's exactly what has happened with Ozempic. Hollywood celebrities and social media have put the GLP-1 agonist in the spotlight. Novo Nordisk (NYSE: NVO) has no complain...
2023-12-02 02:24:45 ET Summary AbbVie has agreed to acquire ImmunoGen in a $10.1 billion all-cash deal, aiming to revitalize its struggling oncology operations. ImmunoGen's recent success with its drug ELAHERE, which received accelerated approval for the treatment of ovarian cance...
2023-12-01 18:35:46 ET More on Eli Lilly Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly Eli Lilly and Company (LLY) Presents at 6th Evercore ISI HealthCONx Conference (Transcript) Eli Lilly: Perfectly Priced Healthcare Giant ...
Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor PR Newswire The first an...
2023-12-01 17:07:17 ET More on Eli Lilly, Novo Nordisk, etc. Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly Eli Lilly and Company (LLY) Presents at 6th Evercore ISI HealthCONx Conference (Transcript) Novo Nordisk: Plenty More Roo...
2023-12-01 14:19:23 ET More on Novo Nordisk Novo Nordisk: Plenty More Room To Run Despite Its Hefty Valuation Novo Nordisk: Massive Reality Check Awaits Greedy Investors Novo Nordisk: Healthy Gains Ahead, EPS Growth Seen, Technical Strength Cantor bullish on ...
2023-12-01 13:56:32 ET Summary Today's news that Pfizer Inc.'s twice-daily oral weight loss drug will be discontinued due to safety concerns has dropped the share price to a new low. The company has struggled all year as its COVID franchise has disintegrated after contributing ~$1...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 07:07:00 ET If your portfolio doesn't have exposure to the biopharma businesses pursuing the development of weight loss medicines, it might be time to consider changing that situation. With an influx of new drugs for sale, and many competitors looking to secure their share of the...
2024-07-30 05:48:00 ET Going into 2024, DexCom 's (NASDAQ: DXCM) shares were up a whopping 14 times over the last 10 years. The company's continuous glucose monitoring (CGM) devices enjoyed tremendous demand from individuals with diabetes. However, last week was the worst for De...
2024-07-29 15:13:21 ET Eli Lilly & Co (NYSE: LLY) has recently experienced a dramatic $123 billion decline in market value. This significant drop follows positive developments from competitors, notably Viking Therapeutics Inc and Roche Holding AG, who made announcements regarding th...